『The Science Behind Cancer Therapy』のカバーアート

The Science Behind Cancer Therapy

The Science Behind Cancer Therapy

著者: Science
無料で聴く

このコンテンツについて

Ever wonder what goes on in the lab to create the next groundbreaking cancer treatment? From immunotherapy and targeted therapies to the latest breakthroughs in diagnostics, The Science Behind Cancer Therapy deme science that is revolutionizing cancer care. Join us, each episode breaks down the jargon and shares the stories behind the discoveries, giving you a front-row seat to the future of oncology.

Whether you're a patient, a caregiver, a student, or simply curious about the science of medicine, this podcast is your essential guide to understanding how we are turning the tide on cancer, one breakthrough at a time.

© 2025 The Science Behind Cancer Therapy
衛生・健康的な生活 身体的病い・疾患
エピソード
  • FOLFOX anti-carcinoma THERAPY: fighting lymphoma
    2025/09/23

    Tertiary lymphoid structures (TLSs) emerge as crucial determinants of anti-tumor immune responses and clinical outcomes. However, their clinical significance and formation mechanisms in hepatocellular carci noma (HCC) remain unclear. Here, we demonstrate that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, leucovorin, and fluorouracil (FOLFOX) significantly enhances TLS formation in HCC tissues, correlating with improved therapeutic efficacy and prolonged progression-free survival in patients with HCC. Mechanistically, HAIC induces lymphotoxin β (LTβ)-expressing central memory T cell (T CM )-like CD4 + T cells, which activate MMP2 + fibroblasts and FOLR2 + CCL4 + macrophages via the LTβ-LTβR axis to drive TLS development. Furthermore, the CXCL12-CXCR4 axis acts as a critical mediator in recruiting these cells to HAIC-treated tumors, thereby facilitating TLS formation and enhancing anti-tumor immunity. These find ings highlight the pivotal role of TLSs in HAIC-induced anti-tumor immunity and their significance as robust prognostic biomarkers, offering potential therapeutic targets to optimize clinical outcomes for patients with HCC.

    続きを読む 一部表示
    17 分
まだレビューはありません